Daré Bioscience Receives $851,796 Grant Payment
The additional tranche supports development of a non-hormonal intravaginal contraceptive for low- and middle-income country settings.
Updated on Nov. 16, 2026 in Health

Daré Bioscience received an additional $851,796 payment under its existing grant agreement, the second-to-last anticipated tranche under the up to approximately $10.7 million agreement. The grant funds research and development of a novel non-hormonal intravaginal contraceptive.
Why it matters
The contraceptive targets unmet needs among women in low- and middle-income country settings, where non-hormonal options may be limited. Future funding under the agreement depends on achieving additional milestones specified in the grant.
The payment is a grant tranche rather than revenue, and it brings cumulative disbursements under the agreement to roughly $9.9 million of the up to $10.7 million total. The final payment timing and the specific milestones required to release it were not specified.
The players
Daré Bioscience, Inc.
Daré Bioscience is a San Diego-based biopharmaceutical company focused on women's health products, including non-hormonal contraceptives.
The details
The funding supports the Phase 3 clinical study of Ovaprene (ClinicalTrials.gov ID: NCT06127199), which was funded in part by the 2024 tranche. Daré Bioscience said the additional funding will allow it to continue advancing its non-hormonal intravaginal contraceptive work.
Timeline
November 2024: Up to $10.7 million grant agreement originally announced.
2024: Initial approximately $5.4 million grant funding received.
November 2025: Additional approximately $3.6 million payment received.
November 16, 2026: Additional $851,796 grant payment announced from San Diego.
Roadmap
The payment continues a funding path that began with the 2024 tranche supporting the Phase 3 Ovaprene study, which is among the few late-stage efforts for non-hormonal intravaginal contraception. Progress through the remaining tranches will depend on the milestones set in the grant agreement, which sets the pace of the program.
Non-hormonal contraceptive options, if the Ovaprene program succeeds, could give women a choice that does not rely on hormones. The funding does not change availability of any product today, and no approved product has resulted from this work yet.
The takeaway
Grant-funded development of non-hormonal contraceptives is advancing in stages, with each payment tied to measurable progress. Readers tracking women's health options can watch for trial milestones that signal whether these products move closer to market.
What happens next
The remaining grant tranche will be released only after Daré Bioscience achieves additional milestones specified in the grant agreement, and no date for that payment has been set.
Further reading
Explore more Women's Health coverage on Wisevoter.
Source note: This article includes information reported by The Manila times.






